CopperNostics—Here We Are Now, Entertain Us!
Diagnosis and endoradiotherapy using copper radioisotopes-defined as Theranostics or, more specifically, <i>CopperNostics</i>-have the potential to play a prominent role in modern precision medicine, as demonstrated by the FDA approval of [<sup>64</sup>Cu]Cu-DOTA-TATE (Detectnet). In this review we highlight current developments in the production, radiochemical purification, quality control, availability, logistics, and regulatory hurdles of the most relevant copper radioisotopes, <sup>60</sup>Cu, <sup>61</sup>Cu, <sup>62</sup>Cu, <sup>64</sup>Cu, and <sup>67</sup>Cu, for nuclear medicine. Radiopharmaceuticals based on their application in registered clinical trials, either as molecular imaging agents, companion diagnostics or therapeutic agents, are also presented addressing unmet medical needs.
Authors
- Martin Walther (ORCID: https://orcid.org/0000-0002-0474-8492)
- Santiago Andrés Brühlmann (ORCID: https://orcid.org/0000-0002-7840-6858)
- Martin Kreller (ORCID: https://orcid.org/0000-0003-2424-3202)
- Oliver Kiss (ORCID: https://orcid.org/0000-0001-7431-0026)
- Klaus Kopka
Institutions
- Helmholtz-Zentrum Dresden-Rossendorf (DE)
- Technische Universität Dresden (DE)
Publication Details
- Journal
- Pharmaceuticals
- Published
- 2026-02-15
- DOI
- https://doi.org/10.3390/ph19020321
- Primary Topic
- Radiopharmaceutical Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00